Jowiseungki decoction affects diabetic nephropathy in mice through renal injury inhibition as evidenced by network pharmacology and gut microbiota analyses

Abstract

Background: Jowiseungki decoction (JSD) is a prescription commonly used for the treatment of diabetic complications or diabetic nephropathy (DN) in traditional medicine clinics. However, the underlying therapeutic mechanisms of JSD are still unclear. Methods: Streptozotocin (STZ)-induced DN mice were administered 100 and 500 mg/kg JSD for 4 weeks, and the therapeutic mechanisms and targets of JSD were analyzed by network pharmacology and gut microbiota analyses. Results: JSD significantly decreased the increase in food and water intake, urine volume, fasting blood glucose, serum glucose and triglyceride levels, and urinary albumin excretion. JSD administration significantly increased the decrease in insulin secretion and creatinine clearance and reduced the structural damage to the kidney tissues. Moreover, JSD administration significantly inhibited the expression of protein kinase C-alpha (PKC-α), transforming growth factor beta-1 (TGF-β1), α-smooth muscle actin (α-SMA), nuclear factor-κB (NF-κB), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in the kidney tissues of DN mice, while it significantly increased the phosphorylation of insulin receptor substrate 1 (IRS-1), phosphatidylinositol-3-kinase (PI3K), and protein kinase B (Akt). In the network pharmacological analysis, JSD obviously influenced phosphatase binding, protein serine/threonine kinase, and mitogen-activated protein kinase (MAPK)-related signaling pathways. Our data suggest that JSD can improve symptoms in STZ-induced DN mice through the inhibition of kidney dysfunction, in particular, by regulating the PKCα/PI3K/Akt and NF-κB/α-SMA signaling pathways. Gut microbiota analysis can help to discover the pharmacomechanisms of the influence of JSD on bacterial diversity and flora structures in DN. Conclusion: JSD can improve the symptoms of DN, and the underlying mechanism of this effect is renal protection through the inhibition of fibrosis and inflammation. JSD can also change bacterial diversity and community structures in DN.

An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome

“…Meanwhile, network pharmacology can provide insights into the molecular mechanisms of herbal prescriptions at the molecular and systematic levels (Zhang et al, 2017c). Recently, some researchers have successfully used the integrated network pharmacology and gut microbiota analysis strategy to explore the interactions between organisms and TCM prescriptions, bringing great inspiration to the mechanism research of FLZP (Gao et al, 2018;Meng et al, 2020). In this study, network pharmacology and gut microbiota analysis were applied to explore the effects of FLZP regulating gut microbiota of IBS-D, which could provide a basis for the clinical application of FLZP treating IBS-D. Commission, 2015).…”

Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM)

“…It decreases renal inflammation and fibrosis by regulating nuclear factor-κB/α-SMA and protein kinase C-alpha/phosphatidylinositol-3-kinase/protein kinase B signaling pathways. In addition, JSD has an impact on modifying the intestinal bacterial composition [163]. In another study conducted by Zhao and his colleagues, they concluded that Tangshen Formula, a Chinese herbal medicine, modulates the GM and decreases renal inflammation.…”

The modulation of gut microbiota by herbal medicine to alleviate diabetic kidney disease – A review

“…BHID is composed of Gypsumfibrosum, Anemarrhena asphodeloides Bunge, Panax ginseng C.A.Mey., Glycyrrhiza glabra L. and Oryzasativa L. seeds. Meng et al (2020) utilized metabolomics combined with intestinal flora analysis to attempt to explain the mechanism of BHID in the treatment of DKD. They found that after oral administration of BHID (0.5 g/kg/d), there was a significant difference in the abundance of Actinobacteria phylum between the BHID-treated group and control groups.…”